Partition Coefficients and Their Uses

Total Page:16

File Type:pdf, Size:1020Kb

Partition Coefficients and Their Uses Chemical Reviews 525 Volume 71, Number 6 December 1971 PARTITION COEFFICIENTS AND THEIR USES ALBERT LEO,* CORWIN HANSCH, AND DAVID ELKINS Department of Chemistry, Pomona College, Claremont, California 91711 Received March 31, 1971 Contents impossible since Chemical Abstracts has not indexed the of the work of the last few decades under the I. Introduction 525 majority subject of reference be made under the name A. Purpose 525 partitioning. While may B. Historical 526 of a compound, this is of very little help in organizing a list II. Theoretical 527 of known values. Actually, in recent years relatively few par- A. Henry’s Law 527 tition coefficients have been determined in studies simply de- B. Nonideal Behavior of Solutes 527 voted to an understanding of the nature of the partition co- C. Thermodynamics of Partitioning Systems 531 efficient. The vast majority have been measured for some D. for Phase 532 Energy Requirements Transfer secondary reason such as the correlation of relative lipophilic III. Experimental Methods 537 character with biological properties of a set of congeners. IV. Linear Free-Energy Relationships In the course of structure-activity studies undertaken by among Systems 538 this over the decade, values for V. Additive-Constitutive Properties 542 laboratory past many partition VI. Uses of Partition Measurements 548 coefficients of drugs have been found in the biochemical and A. Countercurrent Distribution 548 pharmaceutical literature. From references in these papers, B. Measurement of Equilibria 548 many other values have come to light. As these values have C. Relationship to HLB and Emulsion been uncovered, they have been fed into a computer-based Systems 548 “keyed-retrieval” compilation which, while admittedly not D. Measurement of Dissolution and complete, is still far more comprehensive than any yet pub- Partitioning Rate of Drugs 549 lished. E. Liquid Media and Ion-Exchange This compilation is not the primary reason for the present Ion-Selective Electrodes 550 review. Work8 on the correlation of hydrophobic bonding in F. Measurement of Hydrophobic Bonding biochemical with coefficients has been Ability. Structure-Activity Parameters 550 systems partition because the the VII. The Use of Table XVII 551 greatly hindered of lack of any survey of Downloaded via WESTERN CAROLINA UNIV on February 27, 2020 at 16:20:50 (UTC). VIII. Glossary of Terms 554 field. This review is written in the hope that the organization See https://pubs.acs.org/sharingguidelines for options on how to legitimately share published articles. of the scattered works on this subject will be of help to others. However, the more dynamic part of the subject is the use of I. Introduction the partition coefficient in the study of intermolecular forces of organic compounds. This subject, while still in the em- A. PURPOSE bryonic stage, holds promise for the better understanding of the interaction of small organic molecules with biomacro- In spite of the scientific community’s continuing interest over molecules. Equation 1 is one of many known examples9 of a the past 90 years in partitioning measurements, no compre- hensive review of the subject has ever been published. In fact, n r s j no extensive list = of partition coefficients has appeared in the log 0.75 log P + 2.30 42 0.960 0.159 (1) literature. The largest compilation is that of Seidell;1 2345smaller compilations have been made by Collander,2-5 von Metzsch,6 lineal free energy relationship relating two “partitioning-like” and Landolt.7 The task of making a complete listing is nearly processes. In eq 1, C is the molar concentration of organic compound necessary to produce a 1:1 complex with bovine serum albumin via equilibrium dialysis. This partitioning (1) A. Seidell, “Solubility of Organic Compounds,” Vol. II, 3rd ed, Van Nostrand, Princeton, N. J„ 1941. process is related linearly to log P which is the partition co- (2) R. Collander, Physiol. Plant., 7, 420 (1954). efficient of the compound between octanol and water. The (3) R. Collander, Acta Chem. 3, 717 Scand., (1949), number of molecules studied is represented by n, r is the cor- (4) R. Collander, ibid., 4, 1085 (1950). (5) R. Collander, ibid., 5, 774 (1951). (6) F. von Metzsch, Angew. Chem., 65, 586 (1953). (7) Landolt-Bornstein, “Zahlenwerte and Functionen,” Vol. 2, Springer- (8) C, Hansch, Accounts Chem. Res.t 2, 232 (1969). Verlag, Berlin, 1964, p 698. (9) F. Helmer, K. Kiehs, and C. Hansch, Biochemistry, 7, 2858 (1968). 526 Chemical Reviews, 1971, Vol. 71, No. 6 A. Leo, C Hansch, and D. Elkins relation coefficient, and s is the standard deviation from re- coefficient for the benzoic acid monomer and the dimerization gression. Many such linear relationships between solutes constant for the acid in benzene.13 Since benzoic acid exists partitioned in different solvent systems have been uncovered largely as the dimer in benzene at the concentration em- (section IV). A summary of this work should provide a better ployed, the monomer concentration in benzene is propor- understanding of the octanol-water model system and further tional to the square root of its total concentration in that the application of such linear free energy relationships to solvent. Of course, Nernst was also aware that, at low con- “partitioning-like” processes in more complex biological centrations, the concentration of benzoic acid in the aqueous systems. phase would have to be corrected for ionization. Another aspect of this review is to summarize the present This association and dissociation of solutes in different understanding of the recently discovered10 additive-constitu- phases remains the most vexing problem in studying partition tive character of the partition coefficient. This property prom- coefficients. For a true partition coefficient, one must con- ises to be of value in studying the conformation of molecules sider the same species in each phase. A precise definition of in solution. this in the strictest sense is impossible. Since water molecules and solvent molecules will form bonds of varying degrees of B. HISTORICAL firmness with different solutes, any system more complex than rare gases in hydrocarbons and water becomes impossible The distribution of a solute between two phases in which it is to define sharply at the molecular level. Very little attention soluble has been an important subject for experimentation has been given to the fact that solutes other than carboxylic and study for many years. In one form or another this tech- acids may carry one or more water molecules bound to them nique has been used since earliest times to isolate natural into the nonaqueous phase. This is quite possible in solvents products such as the essences of flowers. such as sec-butyl alcohol which on a molar basis contains The first systematic study of distribution between two more molecules of water in the butanol phase than butanol! immiscible liquids which led to a theory with predictive During the early years of the twentieth century a great capabilities was carried out by Berthelot and Jungfleisch.* 11 number of careful partition experiments were reported in the These investigators accurately measured the amounts present literature, most of which were carried out with the objective of at equilibrium of both I2 and Br2 when distributed between determining the ionization constant in an aqueous medium CS2 and water. They also measured the amounts of various of moderately ionized acids and bases. As a point of historical organic acids, H2S04, HC1, and NH3 when distributed between fact, the method did not live up to its early promise, partly ethyl ether and water. From these early investigations came because of unexpected association in the organic solvents the first appreciation of the basic fact that the ratio of the chosen and partly because of solvent changes which will be concentrations of solute distributed between two immiscible discussed in detail in a following section. solvents was a constant and did not on the relative depend After reliable ionization constants became available through volumes of solutions used. other means, partitioning measurements were used to cal- It was concluded from these early observations that there culate the association constants of organic acids in the non- was a small variation in partition coefficient with temperature, aqueous phase as a function of the temperature. This yielded with the more volatile solvent being favored by a temperature values of AH, AS, and AG for the association reaction.14-18 decrease. It was also evident that some systems, notably However, any calculation of self-association constants from succinic acid partitioned between ether and water, did not obey partition data alone can be misleading when hydrate formation their “rule” even in dilute solution, but simple they intuitively occurs.19’20 felt the rule would be justified nonetheless. As early as 1909, Herz21 published formulas which related the In 1891, Nernst made the next significant contribution to partition coefficient (P) to the number of extractions necessary the subject.12 He stressed the fact that the partition coefficient to remove a given weight of solute from solution. His for- would be constant only if a single molecular species were mula, with symbols changed to conform to present usage, is considered as between the two phases. being partitioned as follows. Considered in this light, partitioning could be treated by If W ml of solution contains x0 g of solute, repeat- classical thermodynamics as an equilibrium process where the edly extracted with L ml of a solvent, and xi g of solute re- of molecular of solute to leave tendency any single species — = mains after the first extraction, then (xr0 xi)/L concentra- one solvent and enter another would be a measure of its tion of solute in extracting phase and xi/W = concentration activity in that solvent and would be related in the usual remaining in original solution.
Recommended publications
  • WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/107 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A 61 47/10 (2006.0V) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2012/034361 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 20 April 2012 (20.04.2012) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/480,259 28 April 201 1 (28.04.201 1) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant (for all designated States except US): BOARD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, OF REGENTS, THE UNIVERSITY OF TEXAS SYS¬ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, TEM [US/US]; 201 West 7th St., Austin, TX 78701 (US).
    [Show full text]
  • DRUGS and DRIVING: January 1978 a SELECTED BIBLIOGRAPHY 6
    Technical Report Pocumtotim Pago 1. Rmrr He I. krrmmt Acce#r~mMe. (<izi19 ----- -- J. Ropott Oete DRUGS AND DRIVING: January 1978 A SELECTED BIBLIOGRAPHY 6. Pr~orn~ng~~gan~gotion code ----- . 8. Pmrfomrng Organctat~onUrnport NO. Alan C. Donelson UM-HSRI-78-3 10 Woh Un~tNo (TRAIS) I I. Conttect or Grant No. DOT-HS-7-01530 13. Type of Repoft and Petlod Covmrd ---------- '1 dministration , July 1975 - November 1976 14. Sponsoring Agency Codr This report presents a first supplement to Drugs and Driving: A Selected Bibliography (HS - 802 188), a bibliography of literature dealing with the relationship between drug use (other than alcohol alone) and highway safety. This supplement both updates the parent volume and expands coverage in certafn research areas related to the field of drugs and highway safety. In particular, 1i terature pertaining to drug usage patterns and drug analytical methodology has been included. A detailed description of the 1i terature scope and document selection process is provided. I I The bi bliography consists of four appendices, including a Topical Index, an Author Index, a Title Index, and Abstracts of nearly 400 i articles. A revised topical index was developed to improve user access to document abstracts. Within the topical index are cross-referenced lists of drugs by name and by usage. - ----&* 17. KO? Words 18. Dimhhtion Stotrmmnt Drugs, Drug Impaired Driving, Drug Avai labil ity is unlimited. Document Effect\, Drug Analytical Method01 ogy, may be re1eased to PIational Technical Drug Concentration-Effect Relation- 1 Information Service, Springfield, VA ships, Countermeasures 22161 for sale to public.
    [Show full text]
  • Georgia State Crime Lab Sample Library Georgia State Forensic Drugs
    Georgia State Crime Lab Sample Library Library Listing – 200 spectra This library contains a sampling of spectra from the Georgia State Forensic Drug library. It is only available as an example library with OMNIC spectroscopy software. The description for the complete Georgia State library is shown below. Georgia State Forensic Drugs Library Listing – 1,940 spectra This definitive forensic library is one of the most extensively used collections for the identification of drug substances. The Georgia State Crime Lab Drug Library contains FT-IR spectra of illegal and legal drugs as well as diluents, precursors and other drug-related compounds. The library consists of spectra that were acquired by the Georgia Bureau of Investigation. The samples were secured as pure drug standards from the U.S. Drug Enforcement Administration (DEA), Applied Science Laboratories, U.S. Pharmacopoeial Conventions, Inc., and various pharmaceutical companies. For the majority of samples the material purity is 95% or better and in many cases is greater than 99%. Unless otherwise stated, the samples were prepared for spectral analysis using KBr pellets. Georgia State Crime Lab Sample Library Index Compound Name Index Compound Name 195 (1- 110 CHLORDIAZEPOXIDE IN KBR PHENYLCYCLOHEXYL)ETHYLAMI 93 CHLORO-METHAQUALONE IN NE KBR 106 (1- 187 CHLOROQUINE IN KBR PHENYLCYCLOHEXYL)ETHYLAMI 174 CHLOROQUINE PO4 IN KBR NE 186 CHLORPHENIRAMINE IN KBR 10 1(1,2- 185 CHLORPHENIRAMINE MALEATE THIENYL)CYCLOHEXYLPIPERIDIN IN KBR 9 1-(1-(2- 72 CHLORPROMAZINE IN KBR THIENYL)CYCLOHEXYL)MORPHO
    [Show full text]
  • On the Approximation of the Laws of the Member States Relating to Cosmetic Products (76/768/EEC )
    27 . 9 . 76 Official Journal of the European Communities No L 262/169 COUNCIL DIRECTIVE of 27 July 1976 on the approximation of the laws of the Member States relating to cosmetic products (76/768/EEC ) THE COUNCIL OF THE EUROPEAN COMMUNITIES, regards the composition, labelling and packaging of cosmetic products ; Having regard to the Treaty establishing the Euro­ pean Economic Community, and in particular Whereas this Directive relates only to cosmetic prod­ Article 100 thereof, ucts and not to pharmaceutical specialities and medicinal products ; whereas for this purpose it is necessary to define the scope of the Directive by Having regard to the proposal from the Commission, delimiting the field of cosmetics from that of phar­ maceuticals ; whereas this delimitation follows in particular from the detailed definition of cosmetic Having regard to the opinion of the European Parlia­ products, which refers both to their areas of appli­ ment ( 1 ), cation and to the purposes of their use; whereas this Directive is not applicable to the products that fall Having regard to the opinion of the Economic and under the definition of cosmetic product but are Social Committee (2 ), exclusively intended to protect from disease; whereas, moreover, it is advisable to specify that certain prod­ ucts come under this definition, whilst products Whereas the provisions laid down by law, regulation containing substances or preparations intended to be or administrative action in force in the Member ingested, inhaled, injected or implanted in the human States
    [Show full text]
  • Sedatives and Hypnotics.Docx
    Sedatives and Hypnotics .Hypnotics and sedative drugs are used to produce drowsiness and promote sleep. .These drugs depress the CNS. .A sedative drug decreases activity, excitements whereas a hypnotic drug produces drowsiness and facilitates the onset and maintenance of sleep as a natural sleep. Classification .According to chemical structures, sedative and hypnotics may be classified into following category:- A)-Barbiturates:- It is a cyclic ureids. Generic name R1 R2 R3 Barbital -Et - Et -H Long duration of action Mephobarbital (Methyl -Et -C6H5 -Me Long duration of action phenobarbitone) Phenobarbital -Et - C6H5 -H Long duration of action Allobarbital allyl allyl -H Intermediate duration of action Amobarbital -Et -C5H11 -H Intermediate duration of action Probarbital -Et -CH(CH3)2 -H Intermediate duration of action Pentobarbital -Et -CH(CH3)-(CH2) 2CH3 -H Short duration of action Methohexital -allyl -CH(CH3)-C≡C-CH2CH3 -1-Me Short duration of action Hexobarbital -Me -1-Me Short duration of action Thiopental (2-C=S) -Et -CH(CH3)-(CH2) 2CH3 -H Ultra Short acting barbiturates B)- Benzodiazepines:- R1 O 9 N 1 8 2 3 4 5 R 7 N 2 6 R3 Drug R1 R2 R3 Flurazepam -CH2CH2N(C2H5)2 -Cl -F Temazepam,(3-OH) -Me -Cl -H Quazepam,(2-C==S) -CH2CF3 -Cl -F C)- Non-Barbiturates and Non- Benzodiazepines:- Ex.- • Glutethimide C2H5 C6H5 O N O H • Chloral hydrate Cl OH Cl C OH H Cl • Paraldehyde CH3 O H O H H H C O CH 3 3 SAR of Barbiturates O 4 R1 5 H N R2 3 O 6 2 O N1 R3 • In general , structural changes that in case the lipid solubility, decrease duration of action, accelerate metabolic degradation and increase hypnotic potency.
    [Show full text]
  • Bond Elut Certify Methods Manual
    AGILENT BOND ELUT CERTIFY AND CERTIFY II METHODS MANUAL TABLE OF CONTENTS INTRODUCTION AND OVERVIEW OF THE MANUAL .................................3 M2724 Meperidine (Pethidine) in Urine by GC or GC/MS ........................... 49 SUMMARY OF BOND ELUT CERTIFY AND CERTIFY II M2725 Methadone in Urine by GC or GC/MS ............................................. 50 MIXED MODE EXTRACTION ............................................................................5 M2726 Methaqualone in Urine by GC or GC/MS ........................................ 51 METHOD OPTIMIZATION .................................................................................6 M2727A 6-Monoacetyl Morphine in Urine by GC or GC/MS ........................ 52 PART NUMBERS................................................................................................8 M2727B 6-Monoacetyl Morphine in Urine by LC or LC/MS ......................... 53 SOLVENTS, SOLVENT MIXTURES, REAGENTS, AND SOLUTIONS .............................................................................................11 M2728 Nicotine in Urine by GC or GC/MS ................................................... 54 EQUIPMENT AND ACCESSORIES ................................................................17 M2729 Opiates (Free/Unbound) in Serum, Plasma, or Whole Blood by GC or GC/MS....................................... 55 BOND ELUT CERTIFY EXTRACTION METHODS ........................................ 29 M2730A Opiates in Urine by GC or GC/MS .................................................... 56 M2707A
    [Show full text]
  • The Organic Chemistry of Drug Synthesis
    THE ORGANIC CHEMISTRY OF DRUG SYNTHESIS VOLUME 3 DANIEL LEDNICER Analytical Bio-Chemistry Laboratories, Inc. Columbia, Missouri LESTER A. MITSCHER The University of Kansas School of Pharmacy Department of Medicinal Chemistry Lawrence, Kansas A WILEY-INTERSCIENCE PUBLICATION JOHN WILEY AND SONS New York • Chlchester • Brisbane * Toronto • Singapore Copyright © 1984 by John Wiley & Sons, Inc. All rights reserved. Published simultaneously in Canada. Reproduction or translation of any part of this work beyond that permitted by Section 107 or 108 of the 1976 United States Copyright Act without the permission of the copyright owner is unlawful. Requests for permission or further information should be addressed to the Permissions Department, John Wiley & Sons, Inc. Library of Congress Cataloging In Publication Data: (Revised for volume 3) Lednicer, Daniel, 1929- The organic chemistry of drug synthesis. "A Wiley-lnterscience publication." Includes bibliographical references and index. 1. Chemistry, Pharmaceutical. 2. Drugs. 3. Chemistry, Organic—Synthesis. I. Mitscher, Lester A., joint author. II. Title. [DNLM 1. Chemistry, Organic. 2. Chemistry, Pharmaceutical. 3. Drugs—Chemical synthesis. QV 744 L473o 1977] RS403.L38 615M9 76-28387 ISBN 0-471-09250-9 (v. 3) Printed in the United States of America 10 907654321 With great pleasure we dedicate this book, too, to our wives, Beryle and Betty. The great tragedy of Science is the slaying of a beautiful hypothesis by an ugly fact. Thomas H. Huxley, "Biogenesis and Abiogenisis" Preface Ihe first volume in this series represented the launching of a trial balloon on the part of the authors. In the first place, wo were not entirely convinced that contemporary medicinal (hemistry could in fact be organized coherently on the basis of organic chemistry.
    [Show full text]
  • Basic Analytical Toxicology
    The World Health Organization is a specialized agency of the United Nations with primary responsibility for international health matters and public health. Through this organization, which was created in 1948, the health professions of some 190 countries exchange their knowledge and experience with the aim of making possible the attainment by all citizens of the world by the year 2000 of a level of health that will permit them to lead a socially and economically productive life. By means of direct technical cooperation with its Member States, and by stimulating such coopera­ tion among them, WHO promotes the development of comprehensive health services, the prevention and control of diseases, the improvement of environmental conditions, the development of human resources for health, the coordination and development of biomedical and health services research, and the planning and implementation of health programmes. These broad fields of endeavour encompass a wide variety of activities, such as developing systems of primary health care that reach the whole population of Member countries; promoting the health of mothers and children; combating malnutrition, controlling malaria and other communicable diseases including tuberculosis and leprosy; coordinating the global strategy for the prevention and control of AIDS; having achieved the eradication of smallpox, promoting mass immunization against a number of other preventable diseases; improving mental health; providing safe water supplies; and training health personnel of all categories. Progress towards better health throughout the world also demands international cooperation in such matters as establishing international standards for biological substances, pesticides and pharma­ ceuticals; formulating environmental health criteria; recommending international nonproprietary names for drugs; administering the International Health Regulations; revising the International Statistical Classification of Diseases and Related Health Problems and collecting and disseminating healih statistical information.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Bromisoval | Medchemexpress
    Inhibitors Product Data Sheet Bromisoval • Agonists Cat. No.: HY-B2113 CAS No.: 496-67-3 Molecular Formula: C₆H₁₁BrN₂O₂ • Molecular Weight: 223.07 Screening Libraries Target: Others Pathway: Others Storage: Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month SOLVENT & SOLUBILITY In Vitro DMSO : 300 mg/mL (1344.87 mM; Need ultrasonic and warming) Mass Solvent 1 mg 5 mg 10 mg Concentration Preparing 1 mM 4.4829 mL 22.4145 mL 44.8290 mL Stock Solutions 5 mM 0.8966 mL 4.4829 mL 8.9658 mL 10 mM 0.4483 mL 2.2414 mL 4.4829 mL Please refer to the solubility information to select the appropriate solvent. BIOLOGICAL ACTIVITY Description Bromisoval has anti-inflammatory effects and has been used as an old sedative and hypnotic. In Vitro Bromisoval (BU) suppresses nitric oxide (NO) releasing and proinflammatory cytokine expression in lipopolysaccharide (LPS)-treat BV2 cells, a murine microglial cell line. Bromisoval suppresses LPS-inducing phosphorylation of signal transducer and activator of transcription 1 (STAT1) and expression of interferon regulatory factor 1 (IRF1). The Janus kinase 1 (JAK1) inhibitor filgotinib suppresses the NO release much more weakly than that of Bromisoval, although filgotinib almost completely prevents LPS-inducing STAT1 phosphorylation. Knockdown of JAK1, STAT1, or IRF1 does not affect the suppressive effects of Bromisoval on LPS-inducing NO. A combination of Bromisoval and filgotinib synergistically suppress the NO releasing. The mitochondrial complex I inhibitor rotenone, which does not prevent STAT1 phosphorylation or IRF1 expression, suppresses proinflammatory mediator expression less significantly than Bromisoval.
    [Show full text]
  • 126.10 Drugs and Devices — Misbranding — Labeling. 1. a Drug Or Device Is Misbranded Under Any of the Following Circumstances: A
    1 DRUGS, DEVICES, AND COSMETICS, §126.10 126.10 Drugs and devices — misbranding — labeling. 1. A drug or device is misbranded under any of the following circumstances: a. If its labeling is false or misleading in any particular. b. (1) If in a package form unless it bears a label containing both of the following: (a) The name and place of business of the manufacturer, packer, or distributor. (b) An accurate statement of the quantity of the contents in terms of weight, measure, or numerical count. (2) However, under subparagraph (1), subparagraph division (a), reasonable variations shall be permitted, and exemptions as to small packages shall be allowed, in accordance with rules adopted by the board. c. If any word, statement, or other information required by or under the authority of this chapter to appear on the label or labeling is not prominently placed thereon with such conspicuousness, as compared with other words, statements, designs, or devices, in the labeling, and in such terms as to render it likely to be read and understood by the ordinary individual under customary conditions of purchase and use. d. If it is for use by humans and contains any quantity of the narcotic or hypnotic substance alpha-eucaine, barbituric acid, beta-eucaine, bromal, cannabis, carbromal, chloral, coca, cocaine, codeine, heroin, marijuana, morphine, opium, paraldehyde, peyote, or sulphonmethane; or any chemical derivative of such a substance, which derivative, after investigation, has been designated as habit forming, by rules adopted by the board under this chapter or by regulations adopted by the secretary pursuant to section 502(d) of the federal Act; unless its label bears the name and quantity or proportion of such substance or derivative and in juxtaposition therewith the statement “Warning — May Be Habit Forming”.
    [Show full text]
  • Perspectives in Drug Discovery a Collection of Essays on the History and Development of Pharmaceutical Substances
    Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology National Board of Forensic Medicine Perspectives in Drug Discovery A Collection of Essays on the History and Development of Pharmaceutical Substances Professor Alan Wayne Jones Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine Artillerigatan 12 • SE-587 58 Linköping • Sweden E-mail: [email protected] Internet: www.rmv.se RMV-report 2010:1 ISSN 1103-7660 Copyright © 2010 National Board of Forensic Medicine and Professor Alan Wayne Jones Design and graphic original: Forma Viva, Linköping • Sweden Printed by Centraltryckeriet, Linköping • Sweden, October 2010 Contents Preface Introduction 1. The First Sedative Hypnotics . 13 2. The Barbiturates ......................... 19 3. The Benzodiazepines ..................... 25 4. Narcotic Analgesics . 31 5. Central Stimulant Amines . 39 6. The First Antidepressants .................. 45 7. Antipsychotic Medication ................. 51 8. Aspirin and Other NSAID .................. 59 9. General Anesthetics . 65 10. SSRI Antidepressants . 71 11. Histamine Antagonists .................... 79 12. Anticonvulsants ......................... 87
    [Show full text]